These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11768291)

  • 1. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data.
    Hing JP; Woolfrey SG; Greenslade D; Wright PM
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):465-79. PubMed ID: 11768291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ways to fit a PK model with some data below the quantification limit.
    Beal SL
    J Pharmacokinet Pharmacodyn; 2001 Oct; 28(5):481-504. PubMed ID: 11768292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data.
    Yang S; Roger J
    Pharm Stat; 2010; 9(4):313-30. PubMed ID: 20043295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Handling data below the limit of quantification in mixed effect models.
    Bergstrand M; Karlsson MO
    AAPS J; 2009 Jun; 11(2):371-80. PubMed ID: 19452283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Likelihood based approaches to handling data below the quantification limit using NONMEM VI.
    Ahn JE; Karlsson MO; Dunne A; Ludden TM
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):401-21. PubMed ID: 18686017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.
    Xu XS; Dunne A; Kimko H; Nandy P; Vermeulen A
    J Pharmacokinet Pharmacodyn; 2011 Aug; 38(4):423-32. PubMed ID: 21626437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?
    Hing JP; Woolfrey SG; Greenslade D; Wright PM
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):193-210. PubMed ID: 11381570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of censoring data below an arbitrary quantification limit on structural model misspecification.
    Byon W; Fletcher CV; Brundage RC
    J Pharmacokinet Pharmacodyn; 2008 Feb; 35(1):101-16. PubMed ID: 17963024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model.
    Nguyen TH; Comets E; Mentré F
    J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):499-518. PubMed ID: 22886041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.
    Duval V; Karlsson MO
    Pharm Res; 2002 Dec; 19(12):1835-40. PubMed ID: 12523662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1983 Jun; 11(3):303-19. PubMed ID: 6644555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic parameter estimation: population size versus number of samples.
    Girgis S; Pai SM; Girgis IG; Batra VK
    AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1981 Oct; 9(5):635-51. PubMed ID: 7334463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors.
    Pelekis M; Nicolich MJ; Gauthier JS
    Risk Anal; 2003 Dec; 23(6):1239-55. PubMed ID: 14641898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.
    Keizer RJ; Jansen RS; Rosing H; Thijssen B; Beijnen JH; Schellens JH; Huitema AD
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00131. PubMed ID: 26038706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of collinearity on parameter estimates in nonlinear mixed effect models.
    Bonate PL
    Pharm Res; 1999 May; 16(5):709-17. PubMed ID: 10350015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Evaluation of Statistical Methods for Analyzing Follow-Up Gaussian Laboratory Data with a Lower Quantification Limit.
    Karon JM; Wiegand RE; van de Wijgert JH; Kilmarx PH
    J Biopharm Stat; 2015; 25(4):812-29. PubMed ID: 24906060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.
    Sheiner LB; Grasela TH
    Drug Metab Rev; 1984; 15(1-2):293-303. PubMed ID: 6547663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
    Ette EI; Onyiah LC
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.